ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Investigator-initiated multicenter Phase I study in glioblastoma with CAXII-targeting, 177Lu radiolabeled antibody Fab fragment (LuCaFab) in preparation, led by University of Münster as the sponsor
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster will present a corporate overview and update at the virtual 40th
Grand Pharma has licensed the development, manufacturing and commercialization rights of ITM's Targeted Radionuclide Therapeutic candidates ITM-11 (n.c.a 177Lu-edotreotide) and ITM-41 (n.c.a 177Lu-zoledronate)